[{"id":"d420aa28-774d-4d46-903e-bbe5252407f6","acronym":"TROIKA","url":"https://clinicaltrials.gov/study/NCT03013504","created_at":"2021-01-18T14:49:45.163Z","updated_at":"2024-07-02T16:35:56.290Z","phase":"Phase 3","brief_title":"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients","source_id_and_acronym":"NCT03013504 - TROIKA","lead_sponsor":"Prestige Biopharma Limited","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • epirubicin • Hervelous (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 503","initiation":"Initiation: 02/19/2018","start_date":" 02/19/2018","primary_txt":" Primary completion: 04/19/2019","primary_completion_date":" 04/19/2019","study_txt":" Completion: 01/13/2022","study_completion_date":" 01/13/2022","last_update_posted":"2023-02-07"}]